All the Therapeutic System Drugs
Antibiotics. Amphotericin B 5mg/ml. VIAL (Concent. for susp.for infus.):
10×20ml. IV infus. at 5 mg/kg at a rate of
2.5 mg/kg/hr. See lit.
Tmt. of sev. invas. candidiasis. As 2nd line
therapy for the tmt. of sev. syst. fungal
infec. in pts. who have not responded to
conventional amphotericin B or other
syst. antifung. agents, in those who have
renal impair. or other contra-indic. to
conventional amphotericin B, or in pts.
who have developed amphotericin B
nephrotox.
As 2nd line tmt. for invas. aspergillosis,
cryptococcal meningitis and
disseminated cryptococcosis in HIV pts.,
fusariosis, coccidiomycosis, zygomycosis
and blastomycosis.
C/I: Hypersens.
Antivirals for Treatment of HIV Infections. Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil 245 mg. F.C. TABS.: 30. Adults: 1 tab dly on empty stmch. Under 18 yrs: Not recommend. Eldery: use with caution. Not recommend. in pts. with CLcr<50 ml/min. See lit.
For use alone as a complete regimen or in
comb. with other antiretroviral agents for
the tmt of HIV-1 infect. in adults.
C/I: Hypersens. to the product; Sev. hep.
impair. (CPT, Class C); Co-admin. with
terfenadine, astemizole, cisapride,
midazolam, triazolam, pimozide,
bepridil, or ergot alkaloids (for ex.
ergotamine, dihydroergotamine,
ergonovine, methylergonovine).
Co-admin. with voriconazole. Co-admin.
with herbal prep. cont. St. John’s wort
(Hypericum perforatum).
Cannabinoids. THC 0.3, 0.9, 1.5, 3, 4.5 mg/drop, CBD 0.6, 0.9, 3, 4.5, 6 mg/drop. *This product requires a license for medical cannabis.
BOTTLE. (sublingual drop.): 10gr (330 drops). Dosage should be adjust. individual.
The Israel MOH has outlined in Guidance 106 the 12 indicat. for which med. cannabis is indicated. Accord. to this guidance, the 11 indicat. for this product are:
Chemother-induc. nausea and vomit. (CINV)/ chemother induc. pain.
Metastat. cancer pain.
IBD.
Neuropath. pain.
Spastic. of MS.
Pain in Parkinson's dis.
Cachexia in AIDS.
Tourette's syndr.
Recalcitrant epilep. in adult. (Note: Accord. to Guidance 106, med. cannab. is also indic. for recalcitrant epilep. in ped. pts. but this is not an indicat. for this product)
Palliative care for termin. ill pts.
Post- traum. stress disord.
In general, the use of med. cannabis is indicated in pts. who have adequate. tried and failed convent. ther.
Please refer to Guidance 106 for details.
In addition, for an individ. pt. with a clinical. signific. med. condit. that cannot be adequate. managed by convent. ther. and which is not includ. as one of the 12 approved indicat. (eg autism, fibromyalgia), the physician can appeal to the MOH Committee for Med. Cannabis to ask for approval on an individ. exception. basis.
C/I: Prior, current/ family history (1st degr. relative) of psychos. or schizophr. or schizoaffective disord., a hist. of addict. or substance abuse (include. cannabis use disord.or addict. to alcohol), use in preg.or lact., use in pts. <18 yrs. old, bipol.disord., hypersens. to cannabis, coconut oil, palm kernel oil.
In pts. with hepat. cancer, it is recommend. not to use med. cannab. that contains THC.
See lit.
Chemokine Receptor Antagonist. Maraviroc 150 mg, 300 mg. F.C. TABS: 10, 30, 60, 90, 180 x 150 mg,
300 mg. Depend. on interacts. With
co-admin. antiretrovir. ther. and other
medicin. prods. See lit.
In comb. with other antiretrovir. medicin.
prods., for the tmt. experienced adult pts.
infect. with only CCR5-tropic HIV-
1 detectable.
C/I: Hypersens. to active substance or to
peanut, soya or any excips., pts with
severe renal impair. or ESRD (CrCl <30
ml/ min) who take potent CYP3A4 inh.
or inducers.
Nucleoside Reverse Transcriptase Inhibitor. Lamivudine 150 mg, Zidovudine 300 mg. TABS: 60. 1 tab 2 x dly.
HIV infect. adults and adolesc.
DNA Polymerase Inhibitor. Ganciclovir 500 mg. VIALS: 1, 5. Adults: Initially 5mg/kg
every 12 hrs. (at a constant rate of 1
hr.), every 12 hrs. by I.V. inf. for 14 - 21
days. Maint: 6mg/kg dly. by I.V. infus. 5
days/wk. or 5 mg/kg dly. for 7 days/wk.
Only in the tmt. of CMV retinit. in
immunocompromised pts., prevent. CMV
dis. in transplant pts. at risk for CMV dis.
